Dr Stephen Richard Hill, PHD | |
6516 Burnside Pl, Fayetteville, NC 28311-2907 | |
(910) 257-5132 | |
Not Available |
Full Name | Dr Stephen Richard Hill |
---|---|
Gender | Male |
Speciality | Clinical Psychologist |
Experience | 21 Years |
Location | 6516 Burnside Pl, Fayetteville, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093749194 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103T00000X | Psychologist | 3076 (North Carolina) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Thriveworks Clinical - Florida Inc | 5496173577 | 30 |
News Archive
Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.
The FDA is advising consumers not to eat Alfalfa Sprouts and Spicy Sprouts (which contain alfalfa sprouts mixed with radish and clover sprouts) from Tiny Greens Organic Farm of Urbana, Ill. The sprouts were distributed in 4 oz. and 5 lb. containers to various customers, including farmers' markets, restaurants and groceries, in Illinois, Indiana, Iowa, Missouri and possibly other Midwestern states.
GI Partners ("GI"), a leading mid-market private equity firm, announced today the sale of its portfolio company, Plum Healthcare Group, LLC ("Plum"), one of the fastest growing companies in healthcare services, to Bay Bridge Capital Partners ("Bay Bridge"). The sale of Plum generated a return of approximately three times invested capital for limited partners in GI Partners Fund II L.P.
ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, and it includes a two-year extension based on the application of the proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology.
› Verified 3 days ago
Entity Name | Thriveworks Clinical - Florida Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1396360996 PECOS PAC ID: 5496173577 Enrollment ID: O20200922002675 |
News Archive
Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.
The FDA is advising consumers not to eat Alfalfa Sprouts and Spicy Sprouts (which contain alfalfa sprouts mixed with radish and clover sprouts) from Tiny Greens Organic Farm of Urbana, Ill. The sprouts were distributed in 4 oz. and 5 lb. containers to various customers, including farmers' markets, restaurants and groceries, in Illinois, Indiana, Iowa, Missouri and possibly other Midwestern states.
GI Partners ("GI"), a leading mid-market private equity firm, announced today the sale of its portfolio company, Plum Healthcare Group, LLC ("Plum"), one of the fastest growing companies in healthcare services, to Bay Bridge Capital Partners ("Bay Bridge"). The sale of Plum generated a return of approximately three times invested capital for limited partners in GI Partners Fund II L.P.
ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, and it includes a two-year extension based on the application of the proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Stephen Richard Hill, PHD 2300 Ramsey St # 116, Va Medical Center, Fayetteville, NC 28301-3856 Ph: (910) 488-2120 | Dr Stephen Richard Hill, PHD 6516 Burnside Pl, Fayetteville, NC 28311-2907 Ph: (910) 257-5132 |
News Archive
Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.
The FDA is advising consumers not to eat Alfalfa Sprouts and Spicy Sprouts (which contain alfalfa sprouts mixed with radish and clover sprouts) from Tiny Greens Organic Farm of Urbana, Ill. The sprouts were distributed in 4 oz. and 5 lb. containers to various customers, including farmers' markets, restaurants and groceries, in Illinois, Indiana, Iowa, Missouri and possibly other Midwestern states.
GI Partners ("GI"), a leading mid-market private equity firm, announced today the sale of its portfolio company, Plum Healthcare Group, LLC ("Plum"), one of the fastest growing companies in healthcare services, to Bay Bridge Capital Partners ("Bay Bridge"). The sale of Plum generated a return of approximately three times invested capital for limited partners in GI Partners Fund II L.P.
ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, and it includes a two-year extension based on the application of the proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology.
› Verified 3 days ago
Dr. Mary Beth Barnes, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2300 Ramsey St, Ms 116, Fayetteville, NC 28301 Phone: 910-488-2120 Fax: 910-822-7934 | |
Theodore W. Lane, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1540 Purdue Dr Ste 200, Fayetteville, NC 28303 Phone: 910-867-8889 Fax: 910-487-3061 | |
Jenna Herring, Psychologist Medicare: Medicare Enrolled Practice Location: 806 Hay St, Fayetteville, NC 28305 Phone: 910-860-7008 Fax: 910-221-9006 | |
Dr. Tiffany Nicole Gatling, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 2300 Ramsey St, Fayetteville, NC 28301 Phone: 910-488-2120 | |
Miss Liandra Mercedis Wheeler, LPA Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2940 Breezewood Ave, Fayetteville, NC 28303 Phone: 910-827-6594 Fax: 910-827-6592 | |
Dr. Paul J Dean, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 874 Long Iron Dr, Fayetteville, NC 28312 Phone: 910-960-7510 | |
Mrs. Nicole O Collins, M.A. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 5843 Waters Edge Dr, Fayetteville, NC 28314 Phone: 732-642-4412 |